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Abstract 
Background: Cytokine fusion protein that modulates the immune response holds great potential for cancer immu-
notherapy. IL-2 is an effective treatment against advanced cancers. However, the therapeutic efficacy of IL-2 is limited 
by severe systemic toxicity. Several mutants recombinant IL-2 can increase antitumor activity and minimize systemic 
toxicity. Melittin is an attractive anticancer candidate because of its wide-spectrum lytic properties. We previously 
generated a bifunctional fusion protein melittin-MIL-2, composed of melittin and a mutant IL-2. The melittin-MIL-2 
inhibited the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growth. However, whether this 
antitumor effect could also be used in cancer immunotherapy was unknown. To assess its cancer immunotherapy 
potential, we further investigated its more effective antitumor immune response and antitumor effect against cancers 
of different tissue origins in vitro and in vivo.
Methods: The specific IL-2 activity of the melittin-MIL-2 fusion protein was tested on the cytokine growth dependent 
cell line CTLL-2. The cytolytic activity was detected by standard 4-h 51Cr-release assays. PBMC stimulation in response 
to the melittin-MIL-2 was determined by IFN-γ release assay. We observed the cancer cell proliferation of different tis-
sue origins by MTT assay. The ability of melittin-MIL-2 to inhibit tumor growth in vivo was evaluated by using human 
liver (SMMC-7721 cancer cells), lung (A549 cancer cells) and ovarian (SKOV3 cancer cells) cancer xenograft models. 
To assess the immunity within the tumor microenvironment, the level of some cytokines including IFN-γ, TNF-α, IL-12 
and IL-4 was analyzed by ELISA. We injected the MDA-MB-231 cells and the melittin-MIL-2 into mice, and the anti-
metastatic effect was examined by counting nodules in the lung.
Results: The melittin-MIL-2 was more effective in inducing T cell and NK-cell cytotoxicity. The fusion protein sig-
nificantly increased IFN-γ production in PBMCs. In vitro, the melittin-MIL-2 mediated immune cells killing or directly 
killed the cancer cell lines of different tissue origins. In vivo, the fusion protein exhibited stronger inhibition on the 
growth of transplanted human tumors compared to rIL-2. The melittin-MIL-2 treatment promoted the IFN-γ secretion 
in tumor tissues and decreased the immunosuppressive cells in vivo. Furthermore, the fusion protein reduced lung 
metastasis of breast cancer.
Conclusions: This study provides the evidence that the melittin-MIL-2 can produce stronger immune stimulation 
and antitumor effects, and the fusion protein is a potent candidate for cancer immunotherapy.
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Background
Immunotherapy is one of the most promising approaches 
for future cancer therapy [1–3]. Cancer immunother-
apy is to augment a more effective antitumor immune 
response through increasing active immune cells and 
reversing tumor-induced immunosuppression. Various 
immunotherapy methods, including cytokines, tumor 
vaccines and monoclonal antibodies have exhibited 
potential therapeutic potency in both animal models 
and cancer patients. The satisfactory results of cytokine-
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Cytokines have great potential in cancer immunother-
apy [2]. Interleukin-2 (IL-2) is one of the most success-
ful cytokines applied in tumor immunotherapy, which 
plays a key role in immune regulation and T cell prolif-
eration [4]. IL-2 is an effective option against advanced 
cancers. However, high dosage IL-2 can lead to obvious 
systemic side effects, such as fever, renal dysfunction, 
capillary leakage and hypotension [5, 6]. Furthermore, 
attempts to minimize toxicity by lowering the IL-2 dos-
age have resulted in declined antitumor efficacy as well. 
To improve the therapeutic efficacy of IL-2, it is criti-
cal to develop novel methods without leading to severe 
side effects. Several mutants recombinant IL-2 (MIL-2) 
can augment the antitumor effect and reduce systemic 
toxicity [7–9]. We previously constructed a functional 
mutant IL-2 using site-directed mutagenesis [10]. Cur-
rent research is being aimed at developing combination 
strategies having enhanced antitumor effects with less 
related toxicities [11].
Melittin, the major component of European bee 
venom, has immunoregulatory activity and anticancer 
effect [12–18]. Bee venom can enhance T lymphocytes 
esterase expression in S180 sarcoma mouse and increase 
T lymphocyte function [12]. Melittin augments Th1 cells 
function and is used for the therapy of low immune func-
tion, cancer and viral infection [13]. Melittin inhibits pro-
liferation of different tissue origins cancer cells [14–19]. 
Thus, melittin is a potent antitumor candidate.
In a previous study, we have successfully generated a 
bifunctional fusion protein melittin-MIL-2, composed of 
melittin and a mutant IL-2. The melittin-MIL-2 inhibited 
the growth of human ovarian cancer SKOV3 cells in vitro 
and in  vivo tumor growth [20]. However, whether this 
antitumor effect could also be used in cancer immuno-
therapy was unknown. In this study, we further investi-
gated its more effective antitumor immune response and 
antitumor effects against cancers of different tissue ori-
gins, and evaluated its cancer immunotherapy potential.
Methods
Reagents, cell lines and animals
Recombinant melittin-MIL-2 fusion protein was gener-
ated and stored in our laboratory. Recombinant human 
IL-2 (rhIL-2) was purchased from National Institute for 
the Control of Pharmaceutical and Biological Products 
(Beijing, China). Melittin was purchased from Nanning 
Innovation and Technology Pharmaceutical Company 
(Guangxi, China). Interleukin-2-dependent cytotoxic 
T lymphocyte (CTLL-2) cell line was cultured in RPMI 
1640 supplemented with 10  % fetal bovine serum (FBS) 
and IL-2. Cytokines enzyme linked immunosorbent assay 
(ELISA) kits were purchased from Shanghai Westang 
Biotechnology Company Limited. (Shanghai, China). 
These cytokines include interferon gamma (IFN-γ), 
tumor necrosis factor alpha (TNF-α), interleukin-12 (IL-
12) and interleukin-4 (IL-4). Human liver cancer cells 
SMMC-7721, lung cancer cells A549, ovarian cancer 
cells SKOV3 and breast cancer cells MDA-MB-231 were 
obtained from Cell Bank of Chinese Academy of Sci-
ence, Shanghai, China. BALB/c mice (6  week-old) were 
purchased from Institute of Laboratory Animal Sciences, 
Chinese Academy of Medical Sciences, Beijing, China.
Proliferation assay and cytotoxicity assay
The specific IL-2 activity of the melittin-MIL-2 fusion 
protein was assessed on the cytokine growth depend-
ent cell line CTLL-2. Various concentrations (8.0, 2.0, 
0.5, 0.125 µM) of the melittin-MIL-2 were incubated for 
48  h with 2  ×  104 CTLL-2 cells that had been starved 
of IL-2. One μ Ci of [3H] thymidine was added to the 
medium for the last 18 h and cell proliferation was deter-
mined by [3H] thymidine incorporation. The same dilu-
tions of rhIL-2 were used as standard. Phosphate buffer 
saline (PBS) was used as a negative control. We prepared 
peripheral blood mononuclear cells (PBMCs), CD4+, 
CD8+ T cells and NK cells as described in previous study 
[21]. PBMCs were obtained from three normal, healthy 
donors (Donor A, B, C). The experiments were approved 
by the Institutional Review Board of The Affiliated Hos-
pital of Qingdao University. Mononuclear cells were iso-
lated by Ficoll-Hypaque (Pharmacia Biotech, Uppsala, 
Sweden) gradient separation and cultured in six-well 
plates (5 × 106 cells/5 ml/well) in a humidified incubator 
with 5 % CO2 at 37 °C. Culture was maintained in AIM-V 
medium (Life Technologies, Rockville, USA). At the 
same time, the medium was added same concentration 
(2.0  µM) melittin-MIL-2 or rhIL-2 or melittin. PBS was 
used as a negative control. CD4+, CD8+ T cells and NK 
cells were enriched from PBMCs by negative immuno-
magnetic selection. PBMCs were labeled with the enrich-
ment antibody cocktails for human T cells (CD4+, CD8+) 
and NK cells, and then with magnetic colloid according 
to the product insert supplied by StemCell Technolo-
gies (Vancouver, BC, Canada). The cell suspension was 
then passed through a high-gradient magnetic column 
(0.5-inch diameter) of stainless steel mesh to remove 
unwanted magnetically labeled cells. Cell purity was 
determined to be 85 ± 5 % by flow cytometry. Enriched 
cells were cultured in 24-well plates (1  ×  106 cells/ml/
well) in AIM-V medium. At the same time, the medium 
was added same concentration (2.0 µM) melittin-MIL-2 
or rhIL-2 or melittin. PBMCs, CD4+, CD8+ T cells and 
NK cells were cultured for 3–5  days and used as effec-
tor cells. Cells from hepatocellular carcinoma cell line 
SMMC-7721 were used as target tumor cells. The cyto-
lytic activity was detected by standard 4-h 51Cr-release 
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assays. We washed the targets free of excess 51Cr and 
plated the targets in 96-well plate at 5 ×  103 cells/well. 
Then, we added the effector cells to the wells at various 
effector-to-target ratios. The radioactivity released from 
the lysed tumor cells was measured by a gamma counter. 
The percentage of cytolysis was converted to lytic units 
(LU20/107cells). Each of these experiments was repeated 
three times.
IFN‑γ enzyme linked immunosorbent assay (ELISA)
Peripheral blood mononuclear cells stimulation in 
response to the melittin-MIL-2 fusion protein was deter-
mined by IFN-γ release assay. The ELISA was conducted 
with procedures described in the reagent instruction 
manual supplied by Shanghai Westang Biotechnology 
Company Limited. Here, we performed the experimen-
tal condition with the melittin-MIL-2 fusion protein as 
described for the PBMC proliferation assays. PBMCs 
were obtained from three normal, healthy donors (Donor 
A, B, C). Then, supernatant was extracted 5  days after 
PBMC addition and concentration of IFN-γ was analyzed 
by ELISA. These experiments were repeated three times.
Cancer cells proliferation assay
To observe the dose-dependent inhibition of cancer cell 
proliferation, SMMC-7721 hepatocellular carcinoma 
cells (2  ×  104) were incubated with increasing concen-
trations of melittin-MIL-2 (50, 100, 150, 200  μg/ml). 
PBS was used as a negative control. Cell proliferation 
was determined in hexaplicates after 3  days, using the 
MTT assay. To evaluate the growth inhibition of cancer 
cell lines from different tissue origins, liver cancer cells 
(SMMC-7721), mammary cancer cells (MDA-MB-231), 
ovary cancer cells (SKOV3), gastric cancer cells (SGC-
7901) and lung cancer cells (A549) were used. We plated 
cancer cells in 96-well plates (2000 cells/well) and added 
the melittin-MIL-2 (100  μg/ml) at the beginning of the 
incubation. PBS was used as negative control in all can-
cer cell proliferation experiments. Cell proliferation was 
determined by the MTT assay. Recombinant IL-2 and 
melittin were used as experimental controls in ovar-
ian cancer cells SKOV3 proliferation experiment. We 
determined cell proliferation after 24, 48 or 72  h using 
the MTT assay. During the incubation, we checked the 
dishes every day and replenished media. These assays 
were repeated three times.
Tumor challenge and treatment experiments
In the experiments, human liver (SMMC-7721 cancer 
cells), lung (A549 cancer cells) and ovary (SKOV3 can-
cer cells) cancer xenograft models were used. These can-
cer cells (SMMC-7721: 5 ×  106 cells per animal, A549: 
5 × 106 cells per animal, SKOV3: 2 × 105 cells per animal) 
were subcutaneously injected into female BALB/c mice 
(6 week-old). When tumors became palpable (5–7 days), 
the mice were randomized into groups (5 mice per group) 
and administered intraperitoneally at the indicated time 
points with the melittin-MIL-2 (200 μmol per animal) or 
rIL-2 (200  μmol per animal) or melittin (200  μmol per 
animal). Tumor volumes were measured twice a week. As 
soon as mice produced ascites and had a weight increase 
>30  %, they were sacrificed. The xenograft model (liver 
SMMC-7721 cancer) was used to observe the mice sur-
vival. We carefully observed and recorded the survival of 
each mouse, and calculated overall survival.
Cytokine assay in the tumor tissue
In order to evaluate the immunity efficacy of melittin-
MIL-2 on the breast tumor tissue, we killed the mice 
30  days after tumor challenge and gathered the tumor 
tissue of each mouse. Then, we homogenized the tumor 
tissue in PBS and tested cytokine concentration of each 
sample. The equal amount of each sample was detected 
for IFN-γ, TNF-α, IL-12 and IL-4 using ELISA kits 
obtained from Shanghai Westang Biotechnology Com-
pany Limited (Shanghai, China) according to the manu-
facturer’s instructions. We computed the concentration 
of each cytokine relative to respective standard curves. 
Each group includes six mice.
Determination of anti‑metastasis activities
This experiment was conducted as described previously 
[22, 23]. MDA-MB-231 cells were resuspended in culture 
media at a density of 1.5 × 106 per 150 μL and implanted 
into the mammary fat pad of the female BALB/c mice 
(6  week-old). When a distinct tumor mass (4–5  mm in 
diameter) was detectable (for 3  weeks), the mice were 
equally randomized into two groups (10 mice per group): 
the melittin-MIL-2 (200  μmol per mouse) group and 
control group. The control group received 0.9 % normal 
saline. The melittin-MIL-2 was then administered (once 
every other day) for 60  days by intravenous injection. 
Tumor size was measured once every week. Twenty-
four hours after the final administration, animals were 
weighed and sacrificed. Tumors were weighed and col-
lected. Then, the lungs were removed, washed and fixed 
with Bouin’s solution for 24 h to facilitate the counting of 
tumor nodules as described previously [23]. The number 
of tumor nodules on the whole surface of the lungs was 
counted using a microscope.
Statistical analyses
Data were indicated as mean ± SD. Differences between 
groups were analyzed for statistical significance using 
the Student’s t test. A p value less than 0.05 represented 
a statistically significant difference. SPSS Version 19.0 for 
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Windows software (SSPS Inc., Chicago, USA) was used 
for the calculation.
Results
The melittin‑MIL‑2 induced proliferation and stronger 
cytolytic activity of activated lymphocytes
To evaluate the IL-2 activity of the melittin-MIL-2, we 
compared the fusion protein with rIL-2 for its ability to 
induce proliferation of CTLL-2 (Fig.  1a). PBMCs were 
cultured for 5 days at various concentrations of the melit-
tin-MIL-2, rIL-2 and melittin and their cytolytic activities 
were analyzed against hepatocellular carcinoma cell line 
SMMC-7721. The fusion protein significantly enhanced 
the cytolytic activity of PBMCs compared with the same 
levels of rIL-2 or melittin (Fig. 1b–d). When the melittin-
MIL-2 was used, the cytolytic activity was significantly 
greater compared with rIL-2 or melittin (*p < 0.01) at a 
30:1 effector-to-target ratio (Fig. 1b–d). When tested on 
respective T cells (CD4+, CD8+) and NK cells, a signifi-
cant increase in cytolytic activity was most conspicuous 
in the NK cell population. When the melittin-MIL-2 was 
used, the cytolytic activity of NK cells augmented six-
fold compared with those cultured with rIL-2 or melit-
tin (Fig. 1e). Here, melittin-MIL-2 showed similar activity 
than rIL-2 and stronger cytolytic activity than rIL-2.
The melittin‑MIL‑2 promoted the production of IFN‑γ
We compared the level of IFN-γ in culture supernatants 
of PBMCs that were exposed to various concentrations 
of the melittin-MIL-2 fusion protein. One representative 
IFN-γ ELISA was shown in Fig. 2. Our findings indicated 
a significant increase in the production of IFN-γ by the 
PBMCs in melittin-MIL-2 group compared to rIL-2 or 
melittin (Fig.  2a). When the melittin-MIL-2 fusion pro-
tein was tested on isolated T cells (CD4+, CD8+) and 
NK cells, an increase in the production of IFN-γ was 
observed in all of these cells (Fig. 2b).
The melittin‑MIL‑2 inhibited proliferation of cancer cell 
lines of different tissue origins
We observed the dose-dependent inhibition of prolif-
eration, up to 60  %, when SMMC-7721 hepatocellular 
carcinoma cells were cultured with increasing levels of 
melittin-MIL-2 (Fig. 3a). Moreover, we found the similar 
inhibitory effects in four additional cancer cell lines of 
mammary, lung, ovary and gastric origins (Fig. 3b). Our 
findings demonstrated that melittin-MIL-2 and melit-
tin inhibited cell proliferation of ovarian cancer cells 
SKOV3 in a concentration-dependent manner; rIL-2 did 
not inhibit SKOV3 cell proliferation (Fig. 3c). The growth 
curves of SKOV3 cells were analyzed, following incre-
mental increases in level of melittin-MIL-2 for 24, 48 
and 72 h. In all tested levels, treatment for 48 h was most 
effective. The number of SKOV3 cells was represented as 
a percentage of those cells of the control (0 μM melittin-
MIL-2) cases. The most effective inhibitory concentra-
tion of the melittin-MIL-2 was 4 μM, leading to growth 
inhibition of 74 %.
The melittin‑MIL‑2 inhibited tumor growth and exhibited 
enhanced antitumor activity compared to rIL‑2 in vivo
The ability of melittin-MIL-2 to inhibit growth of cul-
tured cancer cells indicated an antitumor activity in 
animals. This was evaluated by using human liver 
(SMMC-7721 cancer cells), lung (A549 cancer cells) 
and ovary (SKOV3 cancer cells) cancer xenograft mod-
els. The melittin-MIL-2 treatment was started only 
after subcutaneous lumps became palpable. The melit-
tin-MIL-2 induced partial inhibition of all the three 
xenograft models (Fig.  4). We observed no significant 
weight loss in these experiments. Saline injections were 
used in a control group. There were no differences in 
tumor volumes among the different groups up to day 
16 (Fig. 4a). After day 16, mean tumor volumes among 
treatment groups were statistically different (p  <  0.05) 
(Fig.  4a). The melittin-MIL-2 treatment was conspicu-
ously different than control from day 16 to the end 
of the experiment (p  <  0.05) (Fig.  4a). Moreover, the 
melittin-MIL-2 treatment was significantly different 
than rIL-2 treatment from day 20 to the conclusion of 
the experiment (p < 0.05) (Fig. 4a). We observed no dif-
ferences in tumor volumes among the different groups 
up to day 12 (Fig.  4b, c). After day 12, mean tumor 
volumes among treatment groups were statistically 
different (p  <  0.05). The melittin-MIL-2 therapy was 
significantly different than control from day 12 to the 
conclusion of the experiment (p  <  0.05). Furthermore, 
the melittin-MIL-2 therapy was evidently different than 
rIL-2 therapy from day 23 to the end of the experi-
ment (p < 0.05). To analyze the effect of melittin-MIL-2 
treatment for the duration of survival time after tumor 
challenge, we examined the number of living mice daily 
for 60  days. Each group contained six mice. Survival 
evaluation suggested increase in the survival rate of 
melittin-MIL-2 treated mice compared to other treated 
groups. The survival time among the mice treated with 
melittin-MIL-2 was higher than other groups (p < 0.05) 
(Fig.  4d). In short, the melittin-MIL-2 treatment con-
tributed to an antitumor activity towards several dif-
ferent xenograft models and demonstrated enhanced 
antitumor activity compared to rIL-2.
The melittin‑MIL‑2 treatment shaped a local 
immunostimulatory microenvironment
Immunity within the tumor microenvironment acts 
as a key factor for the eradication of cancer. To assess 
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the immunity efficacy, we analyzed the concentrations 
of some cytokines including IFN-γ, TNF-α, IL-12 and 
IL-4 by ELISA. The findings from cytokine assays were 
observed (Fig. 5). The level of IFN-γ among mice treated 
with melittin-MIL-2 was significantly higher than PBS 
group (p < 0.01) and melittin group (p < 0.05) (Fig. 5a). 
The level of IFN-γ among mice treated with rIL-2 was 
also higher than PBS group (p < 0.01) and melittin group 
(p < 0.05) (Fig. 5a). Furthermore, the level of IFN-γ in the 
treated mice with melittin was not significantly differ-
ent from those treated with PBS (Fig. 5a). Data on IL-12 
evaluation indicated no significant difference between 
PBS-treated group and other treated groups except in the 
melittin-treated group. Moreover, the IL-12 secretion in 
melittin-MIL-2 group was lower than rIL-2 and melit-
tin groups (p  <  0.05) (Fig.  5b). In spite of a significant 
decline in the level of IL-4 in the mice treated with melit-
tin-MIL-2 (compared with the PBS- and rIL-2-treated 
groups, p < 0.01), we found no difference between melit-
tin-MIL-2 and melittin groups or between PBS and rIL-2 
groups in terms of IL-4 level (Fig. 5c). Additionally, there 
was no significant difference in the TNF-α level after 
treatment with melittin-MIL-2 and PBS. The TNF-α con-
centration in the melittin-MIL-2 group was lower than 
melittin group (p < 0.01) but higher than rIL-2 (p < 0.01) 
(Fig. 5d).
Fig. 1 The melittin-MIL-2 induced proliferation and stronger cytolytic activity of activated lymphocytes. a The IL-2 activity of melittin-MIL-2 fusion 
protein was tested by its ability to stimulate proliferation of CTLL-2 cells. Various concentrations (8.0, 2.0, 0.5, 0.125 µM) of the fusion protein were 
incubated for 48 h with 2 × 104 CTLL-2 cells that had been starved of IL-2. One μ Ci of [3H] thymidine was added to the medium for the last 18 h, 
and cell proliferation was determined by [3H] thymidine incorporation. The same dilutions of rhIL-2 were used as standard. PBS was used as nega-
tive control (*p < 0.05). b–e The melittin-MIL-2 induced stronger cytolytic activity of PBMCs, specifically NK cells. b–d Representative standard 4-h 
51Cr-release data were shown against the hepatocellular carcinoma cell line SMMC-7721. When the melittin-MIL-2 (2.0 µM) was used, the cytolytic 
activity was significantly greater compared with rIL-2 and melittin alone (*p < 0.01) at a 30:1 effector-to-target ratio (E:T). e Enriched T cells (CD4+, 
CD8+) and NK cells were cultured for 3 days and tested for cytolytic activity. Increase in cytolytic activity was most notable in NK cells. When the 
fusion protein (2.0 µM) was used, cytolytic activity of NK cells increased sixfold compared with those cultured with rIL-2 or melittin alone
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The melittin‑MIL‑2 exhibited anti‑metastasis activities 
in an animal model
To assess the effect of the melittin-MIL-2 on metasta-
sis, we used MDA-MB-231 cells, which were initially 
analyzed in  vitro using a cell proliferation assay. When 
incubated with the melittin-MIL-2, the cells showed a 
growth-inhibitory effect (Fig.  3b). This anti-metastasis 
efficacy was tested by using the melittin-MIL-2 and the 
MDA-MB-231 cells. We examined metastasis by count-
ing nodules in the lung. The administered melittin-MIL-2 
reduced metastasis to the lung by 48 % (Fig. 6).
Discussion
Some studies have shown that it is possible to generate 
a biologically active bifunctional molecule comprising of 
a toxin and a cytokine [24–26]. The antitumor effects of 
bifunctional cytokine fusion proteins are mainly depend-
ent on the molecular constitution, cytokine combina-
tion, and tumor animal model. In a previous study, we 
have successfully generated a bifunctional fusion protein 
melittin-MIL-2 that combines melittin and a mutant IL-2 
into a single molecule [20]. Each component retained 
its functionality, thus simultaneous stimulation of the 
mutant IL-2 and the melittin on target cells, accompa-
nied by their respective function, was obtained. There-
fore, this approach of cancer immunotherapy is feasible 
and promising.
Research suggests that several mutants recombinant 
human IL-2 (MIL-2) can enhance antitumor activity and 
reduce toxicity [8–11]. Thus, we previously constructed 
a functional mutant IL-2 (Arg88/Ala125) using site-
directed mutagenesis [10]. In an attempt to reduce the 
side effects of IL-2 immunotherapy, the current study 
is focusing on developing combination treatments with 
additive antitumor effects and decreased toxicity [11]. 
In this study, the IL-2 activity of melittin-MIL-2 was 
compared with rIL-2 for its ability to induce CTLL-2 
proliferation. The results showed that the fusion protein 
retained its IL-2 functional activity. In the present study, 
the in vitro effects of the melittin-MIL-2 on human lym-
phocyte populations were explored. We observed sig-
nificant increases in proliferation, cytotoxicity and IFN-γ 
production in PBMCs. When analyzed on isolated T 
cells (CD4+, CD8+) and NK cells, a notable increase in 
cytolytic effect was most significant in the NK cells. Sub-
stantial up-regulation of IL-2 receptor ɑ in NK cells may 
partly explain this mechanism. Several cytokines, such 
as IL-2, IL-12 and IL-18, are potent inducers of IFN-γ in 
NK and T cells [27–31]. The tumoricidal effects in vivo 
of IFN-γ result either from a direct action on tumor 
cells or indirectly via the activation of several effec-
tor mechanisms. These include stimulation of T- and 
NK-cell activity, stimulation of MHC antigen expres-
sion, and macrophage activation [28]. In this study, an 
increase in IFN-γ production in PBMCs resulted from 
use of the melittin-MIL-2 fusion protein. These findings 
showed that whether injected systemically or locally at 
the site of tumor, the activation, expansion and possi-
bly the survival of effector cells that interact with tumor 
targets could result from the enhanced effect of the 
melittin-MIL-2, thus increasing the antitumor response. 
Indeed, we should directly compare the activity of the 
melittin-MIL-2 with the activity of the mutated form 
of IL-2 in the present experiments. However, we found 
that the MIL-2 had identical functional property to the 
wild type hIL-2 in our previous study [10]. Accordingly, 
Fig. 2 The melittin-MIL-2 promoted the production of IFN-γ. a Representative IFN-γ ELISA for PBMCs cultured for 3 days with the melittin-MIL-2 
(2 µM) or rIL-2 (2 µM) and melittin (2 µM) alone. PBMCs were obtained from 3 normal, healthy donors (Donor A, B, C). b When tested on isolated T 
cells (CD4+, CD8+) and NK cells, increase in IFN-γ production was observed in all cells treated with the melittin-MIL-2. *p < 0.01 compared to control 
(rIL-2 or melittin)
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we would like to incorporate into our future study to 
directly compare the activity of the fusion construct 
melittin-MIL-2 with the activity of the mutated form of 
IL-2.
Melittin is a small linear peptide consisting of 26 amino 
acids [32]. It has been reported that melittin has multiple 
effects, such as antivirus, antibacteria and anti-inflam-
mation, in various cell types [32–34]. Moreover, previous 
studies have demonstrated that melittin can induce cell 
cycle arrest, growth inhibition, and apoptosis in various 
cancer cells [15, 33–35]. Melittin is a desirable antican-
cer candidate because of its broad-spectrum lytic prop-
erties. Here, proliferation of cancer cell lines of different 
tissue origins was inhibited by the melittin-MIL-2 fusion 
protein. The melittin-MIL-2 directly inhibited cell prolif-
eration of ovarian cancer cells SKOV3 in a concentration-
dependent manner; rIL-2 did not directly inhibit growth 
of SKOV3 cells in  vitro. We observed the maximum 
inhibitory effect of the fusion protein on cell proliferation 
after 48 h. The similar inhibitory effects were tested with 
Fig. 3 The melittin-MIL-2 inhibited proliferation of human tumor cells. PBS was used as negative control in all cancer cell proliferation experiments. 
Cell proliferation was determined by the MTT assay. a To observe the dose-dependent inhibition of cancer cell proliferation, SMMC-7721 hepatocel-
lular carcinoma cells (2 × 104) were incubated with increasing concentrations of melittin-MIL-2. Cell proliferation was determined in hexaplicates 
after 3 days. b To assess the growth inhibition of cancer cell lines from different tissue origins, liver cancer cells (SMMC-7721), mammary cancer cells 
(MDA-MB-231), ovary cancer cells (SKOV3), gastric cancer cells (SGC-7901) and lung cancer cells (A549) were used. We plated cancer cells in 96-well 
plates (2000 cells/well) and added the melittin-MIL-2 (100 μg/ml) at the beginning of the incubation. The indicated cancer cells were incubated for 
3 days with melittin-MIL-2 and cell proliferation was determined (*p < 0.05). c The melittin-MIL-2 inhibited cell proliferation of ovarian cancer cells 
SKOV3 in a concentration-dependent manner; rIL-2 did not inhibit cell proliferation of SKOV3. The most effective inhibitory melittin-MIL-2 concen-
tration was 4 μM, causing growth inhibition of 74 % (*p < 0.05)
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four additional cancer cell lines of mammary, lung, liver 
and gastric origins. Our findings indicated that the melit-
tin-MIL-2 also retained its melittin functional activity. 
In  vitro, the melittin-MIL-2 fusion protein may directly 
kill or mediate immune cells killing the tumor cell lines of 
different tissue origins.
Fig. 4 The melittin-MIL-2 inhibited tumor growth and exhibited enhanced antitumor activity compared to rIL-2 in vivo. These cancer cells 
(SMMC-7721: 5 × 106 cells per animal, A549: 5 × 106 cells per animal, SKOV3: 2 × 105 cells per animal) were subcutaneously injected into female 
BALB/c mice (6 week-old). When tumors became palpable (5–7 days), the mice (n = 5 per group) were randomized into groups and administered 
intraperitoneally at the indicated time points with the melittin-MIL-2 (200 μmol per animal) or rIL-2 (200 μmol per animal) or melittin (200 μmol per 
animal). Tumor volumes were measured twice a week. As soon as mice produced ascites and had a weight increase >30 %, they were killed. The 
xenograft model (liver SMMC-7721 cancer) was used to observe the mice survival. We carefully observed and recorded the survival of each mouse, 
and calculated overall survival. a After day 16, mean tumor volumes among treatment groups were statistically different (p < 0.05). Melittin-MIL-2 
therapy was conspicuously different than control (saline) from day 16 to the end of the experiment (p < 0.05). Moreover, melittin-MIL-2 treatment 
was significantly different than rIL-2 treatment from day 20 to the conclusion of the experiment (p < 0.05). b, c After day 12, mean tumor volumes 
among treatment groups were statistically different (p < 0.05). Melittin-MIL-2 therapy was significantly different than control from day 12 to the 
conclusion of the experiment (p < 0.05). Furthermore, melittin-MIL-2 therapy was evidently different than rIL-2 therapy from day 23 to the end of the 
experiment (p < 0.05). d The survival time among the mice treated with melittin-MIL-2 was higher than other groups (p < 0.05)
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In the present study, the in vivo data demonstrated that 
the melittin-MIL-2 had an antitumorigenic effect towards 
several different human xenograft models and exhibited 
enhanced antitumor activity compared to rIL-2. IL-2 can 
motivate immune cells, including T cells, B cells, mono-
cytes, macrophages, LAK cells and NK cells [36, 37]. A 
mutant IL-2 is ~3000-fold more selective in prompting 
proliferation of T cells and NK cells in  vitro compared 
with human IL-2 and so is assessed in parallel with IL-2 
in mice for antitumor effect. Several mutants recombi-
nant human IL-2 can increase the antitumor effect and 
minimize systemic toxicity [7–9]. Furthermore, melittin 
can enhance immune function by increasing Th1 cells 
function. In addition, several studies have manifested 
that melittin can induce apoptosis, cell cycle arrest and 
growth-inhibition in different tumor cells [15, 33–35]. The 
potent antitumor effect of melittin has been verified in 
animal models [38–40]. Thus, the melittin-MIL-2 showed 
significantly enhanced antitumor activity compared to 
rIL-2. Here, the costimulatory activity of melittin-MIL-2 
could cause the additional signal enhancement, suggest-
ing an obvious advantage of the simultaneous presenta-
tion of melittin and mutant IL-2 in one molecule.
The tumor microenvironment plays a pivotal role in 
determining the tumor eradication or dissemination. This 
environment includes various cell types and soluble com-
ponents, interacting with each other. In diseased states, 
a bidirectional network for suppression or progression 
of tumor tissues is produced by the proportion of immu-
nosuppressive to immunostimulatory cells and compo-
nents such as cytokines [41–43]. Here, we evaluated the 
impact of cytokines on tumor microenvironment. The 
type of cytokines secreted in tumor tissues determines 
the subsequent type of immune response. Increased 
Fig. 5 The melittin-MIL-2 treatment shaped a local immunostimulatory microenvironment. a The level of IFN-γ significantly increased in the treated 
mice with melittin-MIL-2 compared to PBS group (p < 0.05). c The level of IL-4 significantly reduced in the treated mice with melittin-MIL-2 com-
pared to PBS group (p < 0.05). b, d No significant change was observed in quantity of IL-12 and TNF-α among mice treated melittin-MIL-2
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concentration of IFN-γ within tumor sites indicates the 
presence of NK cells in the tumor tissues, which can lead 
to the expression of MHC molecules on the surface of 
tumor cells causing increased cell death rooted in higher 
tumor immunogenicity [44]. Moreover, this case can 
result in prime CD8+ and CD4+ cells that are related to 
efficient tumor inhibition. Along with CD8+ and CD4+ 
T lymphocytes, Th0 subtype of T cells promotes the pro-
duction of INF-γ and suppresses the secretion of IL-4, 
contributing to the proliferation of Th1 subtype over 
Th2 cells in the tumor microenvironment. IL-12, one of 
the potent cytokines, produces a beneficial effect on the 
secretion of IFN-γ from NK, NKT and Th1 cells in gen-
erating antitumor immunity [45–47]. In this study, the 
significant decline of IL-4 but no change in the produc-
tion of IL-12 and TNF-α was observed, which showed 
the activation of Th1 and NK cells in the tumor sites. In 
short, the melittin-MIL-2 promoted the IFN-γ secretion 
in tumor tissues and reduced the immunosuppressive 
cells in vivo. The melittin-MIL-2 treatment could shape a 
local immunostimulatory microenvironment.
The therapy of localized malignancies has achieved 
the substantial advances. However, metastatic cancer 
still requires more effective treatment and remains the 
primary cause of cancer mortality, including breast can-
cer. Approximately 90  % of breast cancer-related deaths 
are attributed to metastasis [48]. It is necessary to effec-
tively improve the prevention or treatment of metas-
tasis and consequently improve the survival of cancer 
patients. Among cancer immunotherapies, cytokine-
based methods have exhibited remarkable anticancer and 
anti-metastatic effect in numerous experimental stud-
ies [49–51]. In particular, IL-2-based immunotherapies 
have been manifested to produce durable, tumor-specific 
immune responses capable of preventing recurrence and 
controlling metastasis. Recent studies have indicated 
that melittin may induce cytotoxic, antitumor, immu-
nomodulatory, and apoptotic effects in different tumor 
cells in vivo or in vitro [33, 35, 52]. Furthermore, melit-
tin exhibits the potential of inhibiting cancer cell metas-
tasis [33, 35, 52]. Here, the melittin-MIL-2 inhibited lung 
metastasis of MDA-MB-231 mammary cancer cells. The 
recombinant melittin-MIL-2 fusion protein could stimu-
late tumor-specific immunity and dampen tumor growth 
and provide systemic protection against metastatic can-
cer. Therefore, new approaches which prevent or inhibit 
cancer metastases are of significant clinical value.
Conclusions
The melittin-MIL-2 fusion protein promoted in  vitro 
expansion and stronger cytolytic activity of activated 
lymphocytes, especially NK cells. The melittin-MIL-2 
induced immune cells killing or directly killed the can-
cer cell lines of different tissue origins in vitro. The fusion 
protein showed potent inhibition on the growth of xeno-
graft tumors compared to rIL-2 in  vivo. The melittin-
MIL-2 treatment could shape a local immunostimulatory 
microenvironment. Furthermore, the melittin-MIL-2 
inhibited lung metastasis of breast cancer. The combina-
tion of melittin and a mutant IL-2 should be considered a 
feasible strategy for enhancing immune cell stimulation 
and antitumor effects. The melittin-MIL-2 fusion protein 
is a promising candidate for cancer immunotherapy.
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Fig. 6 The melittin-MIL-2 reduced lung metastasis of MDA-MB-231 
mammary cancer cells. The number of tumor nodules on the 
whole surface of the lungs was counted using a microscope. The 
administered melittin-MIL-2 reduced metastasis to the lung by 48 % 
(*p < 0.05)
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